188 related articles for article (PubMed ID: 30120857)
1. Mitral cells and the glucagon-like peptide 1 receptor: The sweet smell of success?
Bagnoli E; FitzGerald U
Eur J Neurosci; 2019 Feb; 49(4):422-439. PubMed ID: 30120857
[TBL] [Abstract][Full Text] [Related]
2. A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway.
Kim DS; Choi HI; Wang Y; Luo Y; Hoffer BJ; Greig NH
Cell Transplant; 2017 Sep; 26(9):1560-1571. PubMed ID: 29113464
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease.
Glotfelty EJ; Olson L; Karlsson TE; Li Y; Greig NH
Expert Opin Investig Drugs; 2020 Jun; 29(6):595-602. PubMed ID: 32412796
[TBL] [Abstract][Full Text] [Related]
4. An extended release GLP-1 analogue increases α-synuclein accumulation in a mouse model of prodromal Parkinson's disease.
Bergkvist L; Johnson ME; Mercado G; Steiner JA; Meyerdirk L; Schulz E; Madaj Z; Ma J; Becker K; Li Y; Brundin P
Exp Neurol; 2021 Jul; 341():113693. PubMed ID: 33727096
[TBL] [Abstract][Full Text] [Related]
5. α-Synuclein in the olfactory system in Parkinson's disease: role of neural connections on spreading pathology.
Ubeda-Bañon I; Saiz-Sanchez D; de la Rosa-Prieto C; Martinez-Marcos A
Brain Struct Funct; 2014 Sep; 219(5):1513-26. PubMed ID: 24135772
[TBL] [Abstract][Full Text] [Related]
6. The human olfactory system in two proteinopathies: Alzheimer's and Parkinson's diseases.
Ubeda-Bañon I; Saiz-Sanchez D; Flores-Cuadrado A; Rioja-Corroto E; Gonzalez-Rodriguez M; Villar-Conde S; Astillero-Lopez V; Cabello-de la Rosa JP; Gallardo-Alcañiz MJ; Vaamonde-Gamo J; Relea-Calatayud F; Gonzalez-Lopez L; Mohedano-Moriano A; Rabano A; Martinez-Marcos A
Transl Neurodegener; 2020 Jun; 9(1):22. PubMed ID: 32493457
[TBL] [Abstract][Full Text] [Related]
7. The local GLP-1 system in the olfactory bulb is required for odor-evoked cephalic phase of insulin release in mice.
Montaner M; Denom J; Jiang W; Magnan C; Trapp S; Gurden H
Mol Metab; 2023 Jul; 73():101738. PubMed ID: 37182561
[TBL] [Abstract][Full Text] [Related]
8. The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases.
Rey NL; Wesson DW; Brundin P
Neurobiol Dis; 2018 Jan; 109(Pt B):226-248. PubMed ID: 28011307
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of spinal GLP-1 receptor signaling.
Zhang D; Lv G
Peptides; 2018 Mar; 101():89-94. PubMed ID: 29329976
[TBL] [Abstract][Full Text] [Related]
10. Inducible dopaminergic glutathione depletion in an α-synuclein transgenic mouse model results in age-related olfactory dysfunction.
Kim YH; Lussier S; Rane A; Choi SW; Andersen JK
Neuroscience; 2011 Jan; 172():379-86. PubMed ID: 21055449
[TBL] [Abstract][Full Text] [Related]
11. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action.
Athauda D; Foltynie T
Drug Discov Today; 2016 May; 21(5):802-18. PubMed ID: 26851597
[TBL] [Abstract][Full Text] [Related]
12. Spread of aggregates after olfactory bulb injection of α-synuclein fibrils is associated with early neuronal loss and is reduced long term.
Rey NL; George S; Steiner JA; Madaj Z; Luk KC; Trojanowski JQ; Lee VM; Brundin P
Acta Neuropathol; 2018 Jan; 135(1):65-83. PubMed ID: 29209768
[TBL] [Abstract][Full Text] [Related]
13. A ventral glomerular deficit in Parkinson's disease revealed by whole olfactory bulb reconstruction.
Zapiec B; Dieriks BV; Tan S; Faull RLM; Mombaerts P; Curtis MA
Brain; 2017 Oct; 140(10):2722-2736. PubMed ID: 28969383
[TBL] [Abstract][Full Text] [Related]
14. The incretin hormone glucagon-like peptide 1 increases mitral cell excitability by decreasing conductance of a voltage-dependent potassium channel.
Thiebaud N; Llewellyn-Smith IJ; Gribble F; Reimann F; Trapp S; Fadool DA
J Physiol; 2016 May; 594(10):2607-28. PubMed ID: 26931093
[TBL] [Abstract][Full Text] [Related]
15. Olfaction in Parkinson's disease and related disorders.
Doty RL
Neurobiol Dis; 2012 Jun; 46(3):527-52. PubMed ID: 22192366
[TBL] [Abstract][Full Text] [Related]
16. [Pathophysiological process underlying Parkinson's disease: motor & non-motor symptoms].
Takeda A; Baba T; Kikuchi A; Sugeno N; Hasegawa T; Itoyama Y; Ishioka T; Hirayama K; Mori E
Rinsho Shinkeigaku; 2009 Nov; 49(11):888-9. PubMed ID: 20030239
[TBL] [Abstract][Full Text] [Related]
17. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models.
Hölscher C
Neuropharmacology; 2018 Jul; 136(Pt B):251-259. PubMed ID: 29402504
[TBL] [Abstract][Full Text] [Related]
18. Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease.
Rey NL; Steiner JA; Maroof N; Luk KC; Madaj Z; Trojanowski JQ; Lee VM; Brundin P
J Exp Med; 2016 Aug; 213(9):1759-78. PubMed ID: 27503075
[TBL] [Abstract][Full Text] [Related]
19. Increased dopaminergic cells and protein aggregates in the olfactory bulb of patients with neurodegenerative disorders.
Mundiñano IC; Caballero MC; Ordóñez C; Hernandez M; DiCaudo C; Marcilla I; Erro ME; Tuñon MT; Luquin MR
Acta Neuropathol; 2011 Jul; 122(1):61-74. PubMed ID: 21553300
[TBL] [Abstract][Full Text] [Related]
20. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
